



US009545412B2

(12) **United States Patent**
Cau et al.

(10) **Patent No.:** **US 9,545,412 B2**
(45) **Date of Patent:** **Jan. 17, 2017**

(54) **COMPOSITION AND METHODS USED
DURING ANTI-HIV TREATMENT**

(71) Applicant: **UNIVERSITE D'AIX-MARSEILLE**,
Marseilles (FR)

(72) Inventors: **Pierre Cau**, Puyricard (FR); **Nicolas
Levy**, Marseilles (FR)

(73) Assignee: **UNIVERSITE D'AIX-MARSEILLE**,
Marseille (FR)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/733,725**

(22) Filed: **Jun. 8, 2015**

(65) **Prior Publication Data**

US 2015/0342970 A1 Dec. 3, 2015

Related U.S. Application Data

(63) Continuation of application No. 12/811,474, filed as
application No. PCT/FR2008/001844 on Dec. 31,
2008, now abandoned.

(Continued)

(51) **Int. Cl.**

A01N 37/36 (2006.01)

A61K 31/66 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61K 31/675** (2013.01); **A61K 31/215**
(2013.01); **A61K 31/22** (2013.01); **A61K 45/06**
(2013.01);

(Continued)

(58) **Field of Classification Search**

CPC .. **A61K 31/675**; **A61K 31/66**; **A61K 31/4025**;
A61K 31/366; **A61K 31/22**; **A61K**
31/427; **A61K 31/665**

(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,652,227 A 7/1997 Teronen et al.

5,733,558 A 3/1998 Breton et al.

(Continued)

FOREIGN PATENT DOCUMENTS

EP 1 127 573 A1 8/2001

EP 1 566 177 A1 8/2005

(Continued)

OTHER PUBLICATIONS

Martinez et al. "Management of dyslipidaemia in HIV-infected
patients receiving antiretroviral therapy," *Antiviral Therapy*, 2004,
vol. 9, pp. 649-663.*

(Continued)

Primary Examiner — Shengjun Wang


(74) *Attorney, Agent, or Firm* — Arent Fox LLP

(57)

ABSTRACT

This invention relates to a composition comprising an anti-
HIV treatment and a treatment for side effects of said
anti-HIV treatment in an HIV-infected patient. This inven-
tion is, for example, very useful in the treatment of side
effects caused by certain anti-HIV treatments, for example
premature aging and lipodystrophy, which can be caused by
protease inhibitors or reverse transcriptase inhibitors. The
composition of this invention includes at least one
hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitor, at least one farnesyl-pyrophosphate synthase
inhibitor, and at least one anti-HIV agent. One of the
processes for treating an HIV-infected patient includes, in
any order, the following steps: (i) administration of a mix-
ture including at least one hydroxymethylglutaryl-coenzyme
A (HMG-CoA) reductase inhibitor and at least one farnesyl-
pyrophosphate synthase inhibitor and (ii) administration of
an anti-HIV agent, in which the administrations are con-
comitant, successive or alternative.

15 Claims, 16 Drawing Sheets



(60) Provisional application No. 61/018,688, filed on Jan. 3, 2008.

<i>A61K 31/675</i>	(2006.01)
<i>A61K 31/497</i>	(2006.01)
<i>C07D 239/42</i>	(2006.01)
<i>A61K 31/505</i>	(2006.01)
<i>A61K 31/44</i>	(2006.01)
<i>A61K 31/425</i>	(2006.01)
<i>A61K 31/34</i>	(2006.01)
<i>A61K 31/215</i>	(2006.01)
<i>A61K 31/22</i>	(2006.01)
<i>A61K 45/06</i>	(2006.01)
<i>A61K 31/427</i>	(2006.01)
<i>A61K 31/496</i>	(2006.01)
<i>A61K 31/366</i>	(2006.01)
<i>A61K 31/4025</i>	(2006.01)
<i>A61K 31/665</i>	(2006.01)

CPC *A61K 31/366* (2013.01); *A61K 31/4025*
(2013.01); *A61K 31/427* (2013.01); *A61K*
31/496 (2013.01); *A61K 31/66* (2013.01);
A61K 31/665 (2013.01)

USPC 514/163, 94, 75, 274, 423
See application file for complete search history.

U.S. PATENT DOCUMENTS

5,902,805 A	5/1999	Breton et al.	
8,518,914 B2 *	8/2013	Levy	A61K 31/22 514/108
9,072,757 B2 *	7/2015	Levy	A61K 31/22
2001/0036936 A1	11/2001	Day et al.	
2003/0105121 A1	6/2003	Bihari	
2005/0020517 A1	1/2005	Drees et al.	
2006/0078531 A1	4/2006	Sota	
2006/0275294 A1	12/2006	Omoigui	
2010/0120720 A1	5/2010	Levy et al.	

WO	WO 02/00168	A2	1/2002
WO	WO 2004/024165	A1	3/2004
WO	WO 2004/050077	A1	6/2004
WO	WO 2005/021001	A1	3/2005
WO	WO 2005/074916	*	8/2005
WO	WO 2005/074916	A1	8/2005
WO	WO 2009/112653	A2	9/2009

Kravicik "Update on HIV lipodystrophy," *HIV Clin. Trials*, 2004, vol. 5, No. 3, pp. 152-167.*

Brown et al. "Osteopenia and Osteoporosis in Patient with HIV: a review of current concepts," *Current Infectious Disease Reports*, Mar. 2006, vol. 8, No. 2, pp. 162-170.*

Gordon, et al., "Reduced Adiponectin and HDL Cholesterol without Elevated C-Reactive Protein: Clues to the Biology of Premature Atherosclerosis in Hutchinson-Gilford Progeria Syndrome", *J. Pediatrics*, 2005, 146(3): 336-341.

Fong, et al., "A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria", *Science*, 2006, 311: 1621-1623.

Toth, et al., "Blocking Protein Farnesyltransferase Improves Nuclear Shape in Fibroblasts from Humans with Progeroid Syndromes", *PNAS*, 2005, 102(36): 12873-12878.

Biamonti, et al., "The Gene for a Novel Human Lamin Maps at a Highly Transcribed Locus of Chromosome 19 which Replicates at the Onset of S-phase", *Molecular and Cellular Biology*, 1992, pp. 3499-3506, vol. 12.